#AANAM – Better REFALS Trial Response Seen in ALS Patient Group

#AANAM – Better REFALS Trial Response Seen in ALS Patient Group

292572

#AANAM – Better REFALS Trial Response Seen in ALS Patient Group

Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Amyotrophic lateral sclerosis (ALS) patients with a short disease duration and fast progression showed better responses to Orion’s investigational oral therapy levosimendan (ODM-109), an analysis of Phase 3 REFALS study data found. While the trial failed to meet its goals of showing levosimendan superior to placebo at maintaining patients’ lung function and overall…

You must be logged in to read/download the full post.